2 clinical trials found.
-
A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations
The purpose of the study is to compare standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia ... -
AAML18P1: Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
The purpose of the study is to evaluate how stopping tyrosine kinase inhibitors (TKI) will affect treatment-free remission in patients with chronic myeloid leukemia (CML ...
